However, because of several limitations of the study (e.g., trials included in the meta-analysis were not specifically designed to evaluate cancer outcomes, lack of individual patient data), the validity of these findings has been questioned.Subsequent studies, including a larger, more comprehensive meta-analysis conducted by FDA, have not shown an increased risk of cancer in patients receiving angiotensin II receptor antagonists.

The doctor prescribed Benicar 20 mg (olmesartan medoxomil).It is very expencive.

The antihypertensive effect of olmesartan medoxomil generally is evident within 2 weeks, with a maximum reduction observed after 4 weeks.Dosage of olmesartan medoxomil in pediatric patients is based on weight. The same pediatric study also included 59 patients who were 1-5 years of age; treatment with olmesartan medoxomil (0.3 mg/kg once daily) in this age group did not result in a statistically significant reduction in blood pressure compared with placebo. If necessary, dosage of the fixed combination may be increased after 1-2 weeks for additional blood pressure control (but should not exceed a maximum dosage of 40 mg of olmesartan medoxomil and 10 mg of amlodipine once daily). Sprue-like enteropathy has not been associated with other angiotensin II receptor antagonists to date and is not considered to be a class effect of the drugs.Findings from 2 long-term, randomized, double-blind, placebo-controlled trials (the Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study [ROADMAP] and the Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial [ORIENT]) prompted concerns that high-dose olmesartan may be associated with an increased risk of cardiovascular death in patients with diabetes mellitus. 2.

The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Check with your FSA Administrator about reimbursement procedures for your plan.The FSA Debit Card would not be charged if something is not considered FSA eligible under your plan. Prescription Settings. In one such study (an observational study conducted in a large [more than 300,000 patient-years of exposure] cohort of patients 65 years of age or older), an increased risk of death was observed in patients receiving olmesartan as compared with other angiotensin II receptor antagonists, but only in the subgroup of patients with diabetes mellitus who received the highest dosage of the drug (40 mg daily) for longer than 6 months; in nondiabetic patients, high-dose olmesartan was associated with a lower incidence of death as compared with other angiotensin II receptor antagonists.

If blood pressure response is inadequate with the initial dosage, dosage may be increased as tolerated to 40 mg daily or a diuretic may be added. Experts recommend that all asymptomatic patients with reduced left ventricular ejection fraction (LVEF) (American College of Cardiology Foundation [ACCF]/American Heart Association [AHA] stage B heart failure) receive therapy with an ACE inhibitor and β-blocker to prevent symptomatic heart failure and reduce morbidity and mortality.

Olmesartan medoxomil is used alone or in combination with other classes of antihypertensive agents in the management of hypertension. If needed, dosage of the fixed combination may be increased after 2 weeks. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. The manufacturer states that combined therapy with the commercially available fixed-combination preparation containing 20 mg of olmesartan medoxomil and 12.5 mg of hydrochlorothiazide can be used in patients whose blood pressure is not adequately controlled by monotherapy with olmesartan medoxomil or 25 mg daily of hydrochlorothiazide.

The usual precautions of angiotensin II receptor antagonist or ACE inhibitor therapy in patients with substantial renal impairment should be observed. The manufacturer states that no adjustment in initial olmesartan medoxomil dosage is necessary in geriatric patients or in those with moderate-to-severe hepatic or renal impairment (creatinine clearance less than 40 mL/minute).